Rationale {#section6-2050312118762043}
=========

Hypernatremia is associated with increased incidences of morbidity and mortality across heterogeneous populations, including intensive care units (ICUs), general wards, and outpatient settings.^[@bibr1-2050312118762043][@bibr2-2050312118762043][@bibr3-2050312118762043][@bibr4-2050312118762043][@bibr5-2050312118762043][@bibr6-2050312118762043][@bibr7-2050312118762043][@bibr8-2050312118762043]--[@bibr9-2050312118762043]^ While less than 10% of patients are hypernatremic upon admission ("community-acquired" hypernatremia), up to 26% of medical ICU patients and 10% of surgical ICU patients become hypernatremic during their stay in the ICU,^[@bibr10-2050312118762043],[@bibr11-2050312118762043]^ including as many as half of critically ill patients with sepsis.^[@bibr12-2050312118762043]^ Hospital-acquired hypernatremia (HAH), specifically hypernatremia that develops in the ICU, is associated with increased risk of death with reported crude in-hospital mortality rates ranging from 14% to 48%.^[@bibr10-2050312118762043]^ Morbid outcome associations include prolonged hospital and ICU stay as well as need for dialysis/renal replacement therapy.^[@bibr13-2050312118762043]^ Similar findings have been reported in the pre- and postsurgical setting.^[@bibr14-2050312118762043][@bibr15-2050312118762043]--[@bibr16-2050312118762043]^ Some authors have suggested that incident hypernatremia be used as a quality metric of appropriate care.^[@bibr17-2050312118762043][@bibr18-2050312118762043][@bibr19-2050312118762043]--[@bibr20-2050312118762043]^

Hypervolemic hypernatremia after resuscitation is now common in ICUs and on medical wards accounting for about half of HAH cases in some reports.^[@bibr21-2050312118762043][@bibr22-2050312118762043][@bibr23-2050312118762043]--[@bibr24-2050312118762043]^ One study showed that nearly half of ICU patients with sepsis developed hypernatremia.^[@bibr12-2050312118762043]^ Published literature generally recommends a similar therapeutic strategy to treat community-acquired hypernatremia (CAH) and HAH: correcting a free water deficit with solute-poor/solute-free fluid. Some sources recommend diuretics along with free water replacement in hypervolemic HAH out of a belief that excess iatrogenic sodium loading may contribute to the hypernatremia.^[@bibr1-2050312118762043],[@bibr5-2050312118762043][@bibr6-2050312118762043][@bibr7-2050312118762043]--[@bibr8-2050312118762043]^ Fluids administered for this purpose are "discretionary fluids" and contribute positively to the patient's net fluid balance.^[@bibr25-2050312118762043]^

Accumulating evidence suggests that a positive fluid balance after the initial resuscitation phase worsens outcomes in critically ill patients.^[@bibr26-2050312118762043][@bibr27-2050312118762043]--[@bibr28-2050312118762043]^ This creates a clinical dilemma regarding how best to therapeutically approach volume status in hypernatremic resuscitated patients. Because expert recommendations appear generally to assume a hypovolemic hypernatremic state (as commonly occurs in CAH) and because we were personally unaware of any controlled randomized or observational cohort studies designed to measure the impact of any therapeutic action intended to correct HAH on clinically relevant outcomes among otherwise-similar patients or in animal models, we undertook a structured literature search to identify any studies providing evidence assessing therapeutic interventions to correct hypernatremia in resuscitated adult patients with sepsis or other forms of shock.

Objectives {#section7-2050312118762043}
==========

We searched for any randomized- or observational-controlled trials evaluating the impact of active correction of hypernatremia to eunatremia on any outcomes in adult patients with shock or sepsis that have been adequately resuscitated as assessed by the treating or the research team.

Eligibility criteria {#section8-2050312118762043}
====================

Studies were identified by searching electronic databases (K.S.) and scanning the reference lists of relevant articles (D.E.S. and J.W.Q.). No date limits were applied to the search, but we restricted studies to English language due to time and resource constraints (funding for and availability of translation services). The search was adapted from some of the search domains used in the searches constructed for the NICE guidelines on Intravenous fluid therapy in adults in hospital as appropriate. The search was constructed by the librarian and search terms were reviewed and agreed upon by authors prior to application within the databases.

Information sources {#section9-2050312118762043}
===================

The search was initially constructed, tested, and conducted in MEDLINE (PubMed, 1946 to present) and adapted for Embase (1947 to present), Cochrane Central Register of Controlled Trials (1991 to present), Cochrane Database of Systematic Reviews (2005 to present), DARE (Database of Reviews of Effects, 1991--2015), [ClinicalTrials.gov](http://ClinicalTrials.gov) (2000 to present), and CINAHL (1937 to present), with the index terms being mapped to non-MEDLINE equivalents, as necessary. Additionally, the Index-Catalogue of the Library of the Surgeon General's Office was searched without date limits. The search was applied until 11 February 2017.

Search strategy {#section10-2050312118762043}
===============

1.  1. *Dysnatremias search domain*

2.   A. "Hyponatremia" \[MeSH\]

3.   B. "Hypernatremia" \[MeSH\]

4.   C. hyponatremia\[tiab\] OR hypernatremia\[tiab\] OR dysnatremia\[tiab\] OR hyponatraemia\[tiab\] OR hypernatraemia\[tiab\] OR dysnatraemia\[tiab\] OR hypernatremias\[tiab\] OR hyponatremias\[tiab\] OR dysnatremias\[tiab\] OR hypernatraemias\[tiab\] OR hyponatraemias\[tiab\] OR dysnatraemias\[tiab\] OR "sodium imbalance"\[tiab\] OR "sodium imbalances"\[tiab\]

5.   D. 1A OR 1B OR 1C

6.  2. *Fluid therapy search domain*

7.   A. "time factors"\[mh\]

8.   B. (rapid\[tiab\] OR fast\[tiab\] OR slow\[tiab\] OR slowness\[tiab\] OR slowly\[tiab\]) AND

9.   C. (infuse\[tiab\] OR infuses\[tiab\] OR infusion\[tiab\] OR infusions\[tiab\] OR administration\[tiab\] OR administrate\[tiab\] OR administrates\[tiab\] OR administrations\[tiab\] OR fluid\[tiab\] OR fluids\[tiab\] OR volume\[tiab\])

10.  D. 2B AND 2C

11.  E. (small\[tiab\] OR large\[tiab\] OR high\[tiab\] OR low\[tiab\])

12.  F. (infuse\[tiab\] OR infuses\[tiab\] OR infusion\[tiab\] OR infusions\[tiab\] OR administration\[tiab\] OR administrate\[tiab\] OR administrates\[tiab\] OR administrations\[tiab\] OR fluid\[tiab\] OR fluids\[tiab\] OR volume\[tiab\])

13.  G. 2E AND 2F

14.  H. (restrict\[tiab\] OR restriction\[tiab\] OR restrictive\[tiab\] OR restrictions\[tiab\] OR restrictively\[tiab\] OR conservative\[tiab\] OR conservatively\[tiab\] OR liberal\[tiab\] OR liberally\[tiab\])

15.  I. (fluid\[tiab\] OR fluids\[tiab\] OR regime\[tiab\] OR regimes\[tiab\] OR regimen\[tiab\] OR regimens\[tiab\] OR regimentation\[tiab\] OR regimentations\[tiab\] OR protocol\[tiab\] OR protocols\[tiab\] OR intake\[tiab\] OR intakes\[tiab\])

16.  J. 2H AND 2I

17.  K. (timing\[tiab\] OR delayed\[tiab\] OR intermediate\[tiab\] OR early\[tiab\] OR selective\[tiab\] OR rapid\[tiab\] OR immediate\[tiab\] OR immediately\[tiab\])

18.  L. (fluid\[tiab\] OR fluids\[tiab\] OR therapy\[tiab\] OR therapies\[tiab\] OR intravenous\[tiab\] OR intravenously\[tiab\] OR iv\[tiab\])

19.  M. 2K AND 2L

20.  N. (fluid\[tiab\] OR fluids\[tiab\])

21.  O. bolus\[tiab\])

22.  P. 2N AND 2O

23.  Q. 2A OR 2D OR 2G OR 2J OR 2M OR 2P

24. 3. *Shock, hypovolemia, and sepsis search domain*

25.  A. shock\[mh\] OR "Hypovolemia"\[MeSH:noexp\] OR hypotension\[MeSH:noexp\] OR dehydration\[MeSH:noexp\] OR "fluid therapy"\[majr\]

26.  B. (fluid\[tiab\] OR fluids\[tiab\] OR volume\[tiab\] OR volumes\[tiab\] OR volumetric\[tiab\])

27.  C. (restoration\[tiab\] OR restore\[tiab\] OR restores\[tiab\] OR restorations\[tiab\] OR resuscitation\[tiab\] OR resuscitations\[tiab\] OR resuscitate\[tiab\] OR resuscitative\[tiab\] OR replace\[tiab\] OR replaces\[tiab\] OR replacement\[tiab\] OR replacements\[tiab\] OR replacing\[tiab\] OR deplete\[tiab\] OR depletes\[tiab\] OR depleting\[tiab\] OR depletion\[tiab\] OR depletions\[tiab\] OR deficiency\[tiab\] OR deficient\[tiab\] OR deficiencies\[tiab\])

28.  D. 3B AND 3C

29.  E. (hypotension\[tiab\] OR hypotensive\[tiab\] OR hypotensions\[tiab\])

30.  F. (resuscitation\[tiab\] OR resuscitations\[tiab\] OR resuscitate\[tiab\] OR resuscitative\[tiab\])

31.  G. 3E AND 3F

32.  H. (shock\[tiab\] OR resuscitation\[tiab\] OR resuscitations\[tiab\] OR resuscitate\[tiab\] OR resuscitative\[tiab\] OR hypotention\[tiab\] OR hypotensive\[tiab\] OR hypotensions\[tiab\] OR dehydrate\[tiab\] OR dehydration\[tiab\] OR dehydrates\[tiab\] OR dehydrations\[tiab\] OR dehydrating\[tiab\])

33.  I.  (fluid\[tiab\] OR fluids\[tiab\])

34.  J. 3H AND 3I

35.  K. (hypovolemia\[tiab\] OR hypovolaemia\[tiab\] OR hypovolemic\[tiab\] OR hypovolaemic\[tiab\] OR hypovolemics\[tiab\] OR hypovolaemics\[tiab\] OR "sepsis syndrome"\[tiab\] OR "sepsis syndromes"\[tiab\] OR "circulatory failure"\[tiab\] OR "circulatory failures"\[tiab\])

36.  L. (circulatory\[tiab\] OR hemodynamic\[tiab\] OR haemodynamic\[tiab\])

37.  M. (failure\[tiab\] OR failures\[tiab\] OR insufficiency\[tiab\] OR insufficiencies\[tiab\] OR insufficient\[tiab\] OR abnormality\[tiab\] OR abnormalities\[tiab\] OR instability\[tiab\] OR instabilities\[tiab\])

38.  N. 3L AND 3M

39.  O. (shock\[tiab\] OR resuscitation\[tiab\] OR resuscitations\[tiab\] OR resuscitate\[tiab\] OR resuscitative\[tiab\] OR hypotension\[tiab\] OR hypotensive\[tiab\] OR hypotensions\[tiab\] OR dehydrate\[tiab\] OR dehydration\[tiab\] OR dehydrates\[tiab\] OR dehydrations\[tiab\] OR dehydrating\[tiab\])

40.  P. 3A OR 3D OR 3G OR 3J OR 3K OR 3N OR 30

41. 4. *Adult filter*

42.  A. Child\[mh\]

43.  B. child\[tiab\] OR children\[tiab\] OR infant\[tiab\] OR infants\[tiab\] OR neonate\[tiab\] OR neonates\[tiab\] OR neonatal\[tiab\] OR newborn\[tiab\] OR newborns\[tiab\] OR boy\[tiab\] OR boys\[tiab\] OR girl\[tiab\] OR girls\[tiab\] OR adolescent\[tiab\] OR adolescents\[tiab\]

44.  C. 4A OR 4B

45.  D. Adult\[mh\]

46.  E. adult\[tiab\] OR adults\[tiab\]

47.  F. 4D OR 4F

48.  G. 4C NOT 4F

49. 5. *Humans filter*

50.  A. Animals\[MeSH\]

51.  B. Humans\[MeSH\]

52.  C. 5A NOT 5B

53. 6. *Final search combination*

54.  ((1D AND (2Q OR 3P)) NOT 4G) NOT 5C

Study records {#section11-2050312118762043}
=============

Data management {#section12-2050312118762043}
---------------

After deduplication in RefWorks, citations were exported to Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) in a spreadsheet format. This file was then duplicated and given to both reviewers (J.W.Q. and D.E.S.) to work independently and to avoid potential bias.

Selection process {#section13-2050312118762043}
-----------------

After deduplication, 3746 article abstracts were identified and individually reviewed to determine whether any controlled trials supporting correction to eunatremia in the formerly described search criteria were present. As the spreadsheet had been duplicated, the reviewers were not aware of the other's review. There was no disagreement in the final conclusion, so no consensus was needed for resolution of inclusion decisions ([Figure 1](#fig1-2050312118762043){ref-type="fig"}).

![PRISMA flow diagram of systematic review.](10.1177_2050312118762043-fig1){#fig1-2050312118762043}

Data collection process {#section14-2050312118762043}
-----------------------

No randomized or observational-controlled studies were identified that assessed the impact of any active therapeutic maneuver intended to correct serum sodium concentrations on any outcome in resuscitated adult patients with resolving sepsis or other shock. Less exhaustive supplementary searches failed to identify similar supporting literature among pediatric, general hospitalized in-patient, or animal populations. We identified two small randomized studies evaluating the effectiveness of diuretics in manipulating sodium concentrations in critically ill patients, but these studies targeted a normonatremic population and were not intended to assess clinically important outcomes.^[@bibr29-2050312118762043],[@bibr30-2050312118762043]^

Discussion {#section15-2050312118762043}
==========

Our systematic review did not identify a single controlled study evaluating the impact of any active measure intended to correct hypernatremia in resuscitated patients with sepsis or other forms of shock on any clinically relevant endpoints. Although not the primary focus of our search, we also failed to identify any study demonstrating that free water or hypotonic fluid administration effectively reduces serum sodium concentrations in this setting.

The association between hypernatremia and increased morbidity and mortality is well established in critically ill patients.^[@bibr1-2050312118762043],[@bibr5-2050312118762043][@bibr6-2050312118762043][@bibr7-2050312118762043]--[@bibr8-2050312118762043]^ However, evidence to establish the extent to which this association reflects causal mediation versus confounding is limited. Recent analyses suggest that existing prediction formulas cannot accurately predict changes in serum sodium in hyponatremic^[@bibr31-2050312118762043]^ or hypernatremic^[@bibr32-2050312118762043]^ in-patients and that hypernatremia in critically ill patients is not adequately explained by excess sodium administration or a water deficit.^[@bibr33-2050312118762043]^ One reasonable alternative hypothesis is that hypernatremia is primarily a marker of severe illness in resuscitated critically ill patients rather than a direct cause of poor outcomes. The recent observation that fluctuations in serum sodium concentrations even within a normal range carries increased risk of death^[@bibr34-2050312118762043]^ suggests that absolute serum sodium concentration may be less important than the loss of homeostatic regulation that results in hypernatremia and supports such a hypothesis.

Accumulating evidence challenges the traditional equilibration model of sodium balance whose assumptions underlie accepted treatment strategies for hypernatremia.^[@bibr35-2050312118762043]^ Skin, skeletal muscle, bone, and cartilage are known to act as reservoirs of sodium.^[@bibr35-2050312118762043][@bibr36-2050312118762043][@bibr37-2050312118762043]--[@bibr38-2050312118762043]^ These reservoirs do not always equilibrate with water and are not controlled by the kidney^[@bibr39-2050312118762043]^ and may be more rapidly mobilized than previously recognized.^[@bibr40-2050312118762043]^ Additional evidence indicates that sodium is intimately tied to immune function and regulation, including inflammation and infection^[@bibr41-2050312118762043],[@bibr42-2050312118762043]^ leading some authors to theorize that a hypertonic environment may serve as a host defense.^[@bibr42-2050312118762043]^ The interplay of these systems during metabolically stressful events provides a mechanism by which sepsis and other forms of shock might result in an "intrinsic" form of hypernatremia independent of volume status.

Given the demonstrated morbidity associated with hypervolemia in critically ill patients,^[@bibr27-2050312118762043],[@bibr43-2050312118762043][@bibr44-2050312118762043]--[@bibr45-2050312118762043]^ the established benefits of "deresuscitation" in such patients,^[@bibr43-2050312118762043],[@bibr46-2050312118762043]^ and the absence of evidence of improved outcomes with volume administration to treat hypernatremia in resuscitated patients, we believe that a cautiously "salt-tolerant/fluid-restricted" therapeutic strategy is at least as well supported by existing research as is the dominant "salt-intolerant/fluid-liberal" paradigm.

There are limitations to our research. Our search required at least the search terms and the abstract be available in English. In addition, we may have overlooked gray literature on the topic such as doctoral dissertations or conference proceedings that were not published as supplements to medical journals.

Conclusion {#section16-2050312118762043}
==========

We did not identify any randomized or observational-controlled trials evaluating the use of active measures to correct hypernatremia in resuscitated patients recovering from critical illness. It is apparent that the existing body of scientific knowledge pertaining to sodium metabolism and homeostasis in critically ill patients is distressingly sparse and is inadequate to meaningfully inform therapeutic decisions. Additional animal and clinical data are needed to empirically establish (1) the mechanisms driving hypernatremia in critically ill patients, (2) appropriate indications for therapeutic correction of hypernatremia following resuscitation, and (3) effective therapeutic strategies for improving clinically important outcomes in hypernatremic resuscitated critically ill patients.
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